The results presented in this study suggest a dynamic interplay between methylation and other posttranslational modifications of E2F1 in breast cancer cells, in which the in vivo levels of methylated and unmethylated E2F1 are determined by the opposing actions of Set9 and LSD1 [6], [7]. Here, KDM1A is linked to breast carcinoma.